AGL Earnings

AGL reported its FY2025Q3 earnings on 2025-11-04, showcasing a revenue of 1.44B against an estimate of 1.50B, resulting in a -4.46% surprise. The EPS was -0.27, surpassing the expected -0.18 by -50%. The stock experienced a 4.05% price change on the earnings day and a -8.95% change over the next five days, reflecting market reactions to the results.

Following AGL's FY2025Q3 earnings announcement on 2025-11-04, the stock price moved by 4.05% on the day of the release. Over the subsequent five days, it saw a -8.95% change. Historically, AGL's stock price tends to shift by an average of 6.28% in the 10 days leading up to earnings and -13.21% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate AGL's annual revenue to reach 1.77B, while the EPS is projected at 0.06. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -0.07% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AGL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -0.07%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AGL's stock price typically moves by 6.28% in the 10 days before its earnings and -13.21% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.06 and revenue of 1.77B.

The earnings call summary presents mixed signals: while there are improvements in cash position and some positive financial metrics, the overall financial performance remains negative with significant losses and cost trends. The Q&A section highlights concerns about cost trends and unclear management responses, which could weigh on investor sentiment. The company's strategic focus on cost reduction and improved payer contracts is promising, but the lack of clear guidance on certain issues tempers optimism. Considering the company's market cap, the stock price is likely to remain relatively stable, resulting in a neutral sentiment.